Search

Author/Creator O'Connor, Owen A.

2. A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. (21st February 2017)

Authors:
Sawas, Ahmed; Farber, Charles M.; Schreeder, Marshall T.; Khalil, Mazen Y.; Mahadevan, Daruka; Deng, Changchun; Amengual, Jennifer E.; Nikolinakos, Petros G.; Kolesar, Jill M.; Kuhn, John G.; Sportelli, Peter; Miskin, Hari P.; O'Connor, Owen A.
Journal:
British journal of haematology
Issue:
Volume 177:Number 2(2017)
Page Start:
243
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Issue 7 (3rd July 2017)

Authors:
Bartlett, Nancy L.; Smith, Mitchell R.; Siddiqi, Tanya; Advani, Ranjana H.; O'Connor, Owen A.; Sharman, Jeff P.; Feldman, Tatyana; Savage, Kerry J.; Shustov, Andrei R.; Diefenbach, Catherine S.; Oki, Yasuhiro; Palanca-Wessels, Maria Corinna; Uttarwar, Mayur; Li, Martha; Yang, Jing; Jacobsen, Eric D.
Journal:
Leukemia & lymphoma
Issue:
Volume 58:Issue 7(2017)
Page Start:
1607
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. (16th December 2016)

Authors:
Kalac, Matko; Lue, Jennifer K.; Lichtenstein, Emily; Turenne, Ithamar; Rojas, Celeste; Amengual, Jennifer E.; Sawas, Ahmed; Deng, Changchun; Mapara, Markus Y.; Connors, Joseph M.; Kuruvilla, John; O'Connor, Owen A.
Journal:
British journal of haematology
Issue:
Volume 180:Number 5(2018)
Page Start:
757
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment. (29th May 2016)

Authors:
Zhao, Baiteng; Chen, Robert; O'Connor, Owen A.; Gopal, Ajay K.; Ramchandren, Radhakrishnan; Goy, Andre; Matous, Jeffrey V.; Fasanmade, Adedigbo A.; Manley, Thomas J.; Han, Tae H.
Journal:
British journal of clinical pharmacology
Issue:
Volume 82:Number 3(2016:Sep.)
Page Start:
696
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. CYP3A‐Mediated Drug–Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30‐Positive Hematologic Malignancies. (10th June 2013)

Authors:
Han, Tae H.; Gopal, Ajay K.; Ramchandren, Radhakrishnan; Goy, Andre; Chen, Robert; Matous, Jeffrey V.; Cooper, Maureen; Grove, Laurie E.; Alley, Stephen C.; Lynch, Carmel M.; O'Connor, Owen A.
Journal:
Journal of clinical pharmacology
Issue:
Volume 53:Number 8(2013:Aug.)
Page Start:
866
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗